2023
Sporadic pituitary adenoma with somatic double-hit loss of MEN1
Hong C, Alanya H, DiStasio M, Boulware S, Rimmer R, Omay S, Erson-Omay E. Sporadic pituitary adenoma with somatic double-hit loss of MEN1. Pituitary 2023, 26: 488-494. PMID: 37438451, DOI: 10.1007/s11102-023-01336-1.Peer-Reviewed Original Research
2020
Association of race and ethnicity to incident epilepsy, or epileptogenesis, after subdural hematoma.
Brown SC, King ZA, Kuohn L, Kamel H, Gilmore EJ, Frontera JA, Murthy S, Kim JA, Omay SB, Falcone GJ, Sheth KN. Association of race and ethnicity to incident epilepsy, or epileptogenesis, after subdural hematoma. Neurology 2020, 95: e2890-e2899. PMID: 32907969, PMCID: PMC7734738, DOI: 10.1212/wnl.0000000000010742.Peer-Reviewed Original ResearchConceptsSubdural hematomaEmergency departmentMultivariable Cox regressionRetrospective cohort studyMedical risk factorsDevelopment of epilepsyNontraumatic subdural hematomaAssociation of raceDiagnosis of epilepsyCohort studyPrimary outcomeRenal diseaseStatus epilepticusWhite patientsBlack patientsHospital revisitsCox regressionBlack raceDiagnosis codesRisk factorsClaims dataInjury severityEpilepsyDrug useSurvival analysis
2017
Do craniopharyngioma molecular signatures correlate with clinical characteristics?
Omay SB, Chen YN, Almeida JP, Ruiz-Treviño AS, Boockvar JA, Stieg PE, Greenfield JP, Souweidane MM, Kacker A, Pisapia DJ, Anand VK, Schwartz TH. Do craniopharyngioma molecular signatures correlate with clinical characteristics? Journal Of Neurosurgery 2017, 128: 1473-1478. PMID: 28707994, DOI: 10.3171/2017.1.jns162232.Peer-Reviewed Original ResearchConceptsPapillary craniopharyngiomasAdamantinomatous craniopharyngiomaMutation groupPostoperative clinical symptomsSubgroup of tumorsMolecular signaturesWeill Cornell Medical CollegeND tumorsClinical characteristicsCornell Medical CollegeClinical symptomsClinical variablesGroup tumorsRadiographic featuresResults HistologyBRAF mutationsCraniopharyngiomaAge groupsMedical CollegeTumorsExome sequencing studiesCTNNB1 mutationsOutcome variablesHistologyPatients
2015
Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis
Erson-Omay EZ, Çağlayan AO, Schultz N, Weinhold N, Omay SB, Özduman K, Köksal Y, Li J, Serin Harmancı A, Clark V, Carrión-Grant G, Baranoski J, Çağlar C, Barak T, Coşkun S, Baran B, Köse D, Sun J, Bakırcıoğlu M, Moliterno Günel J, Pamir MN, Mishra-Gorur K, Bilguvar K, Yasuno K, Vortmeyer A, Huttner AJ, Sander C, Günel M. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-Oncology 2015, 17: 1356-1364. PMID: 25740784, PMCID: PMC4578578, DOI: 10.1093/neuonc/nov027.Peer-Reviewed Original ResearchConceptsHigh-grade gliomasSomatic POLE mutationsPOLE mutationsMalignant high-grade gliomasLonger progression-free survivalProgression-free survivalSomatic mutationsOverall survivalPediatric patientsBetter prognosisClinical featuresImproved prognosisClinical behaviorImmune cellsBizarre cellsAggressive formGlioblastoma multiformeDisease pathophysiologyMolecular subgroupsHomozygous germline mutationGermline mutationsPrognosisGlioma subtypesComprehensive genomic analysisDistinct subgroups